English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A sensitive and specific LC-MS/MS assay for the quantitative determination of anticancer agent EO9 and its conversion products EO5a and EO9-Cl in human and dog urine is presented. A 20-μL-urine aliquot was spiked with a mixture of deuterated internal standards EO9-d3 and EO5a-d4 and diluted with 180 L 0.1 M ammonium acetate - methanol (7:3, v/v). Next, 25 μL-volumes were injected onto the HPLC system. Separation was achieved on a 150  2.1 mm C18 column using an alkaline eluent (1 mM ammonium hydroxide - methanol (gradient system)). Detection was executed by positive ion electrospray followed by tandem mass spectrometry. The assay quantifies a range from 0.1 g/mL to 50  g/mL for EO9, from 0.2  g/mL to 50  g/mL for EO5a and 0.1  g/mL to 4  g/mL for EO9-Cl using 20 μL of stabilized urine samples. Validation results demonstrate that EO9, EO5a and EO9-Cl concentrations can be accurately and precisely quantified in human and dog urine. This assay is used now to support pre-clinical and clinical pharma- cologic studies with intravesically administered EO9.

the open chemical and biomedical methods journal

Simultaneous Quantitative Analysis of EO9 (Apaziquone) and its Conversion Products EO5a and EO9-Cl in Human and Dog Urine by High-Performance Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry